Stocklytics Platform
Asset logo for symbol IONS
Ionis Pharmaceuticals
IONS52
$47.77arrow_drop_down4.15%-$2.07
Asset logo for symbol IONS
IONS52

$47.77

arrow_drop_down4.15%

Performance History

Chart placeholder
Key Stats
Open$49.36
Prev. Close$47.57
EPS-2.67
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range48.62
50.71
52 Week Range35.95
54.44
Ratios
EPS-2.67

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$910.23
Perf. (24h)
arrow_drop_down3.33%-$31.35
Market Cap$841.10B
Price$572.65
Perf. (24h)
arrow_drop_up4.33%$23.78
Market Cap$464.20B
Price$156.45
Perf. (24h)
arrow_drop_up3.60%$5.44
Market Cap$360.27B
Price$125.73
Perf. (24h)
arrow_drop_up0.23%$0.29
Market Cap$326.65B

About Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Brett P. Monia Ph.D.
Headquarters
Carlsbad
Employees
796
Exchange
NASDAQ
add Ionis Pharmaceuticals  to watchlist

Keep an eye on Ionis Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Ionis Pharmaceuticals 's (IONS) price per share?

The current price per share for Ionis Pharmaceuticals (IONS) is $47.77. The stock has seen a price change of -$2.07 recently, indicating a -4.15% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Ionis Pharmaceuticals (IONS)?

For Ionis Pharmaceuticals (IONS), the 52-week high is $54.44, which is 13.96% from the current price. The 52-week low is $35.95, the current price is 32.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Ionis Pharmaceuticals (IONS) a growth stock?

Ionis Pharmaceuticals (IONS) has shown an average price growth of 0.41% over the past three years. It has received a score of 54 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Ionis Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Ionis Pharmaceuticals (IONS) stock price performance year to date (YTD)?

As of the latest data, Ionis Pharmaceuticals (IONS) has a year-to-date price change of -9.65%. Over the past month, the stock has experienced a price change of 17.2%. Over the last three months, the change has been 15%. Over the past six months, the figure is -6.39%. Looking at a longer horizon, the five-year price change stands at -29.34%.

help
Is Ionis Pharmaceuticals (IONS) a profitable company?

Ionis Pharmaceuticals (IONS) has a net income of -$366.29M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -125.12% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $787.65M, with a revenue growth rate of 34.18%, providing insight into the company's sales performance and growth. The gross profit is $778.51M. Operating income is noted at -$353.73M. Furthermore, the EBITDA is -$354.61M.

help
What is the market capitalization of Ionis Pharmaceuticals (IONS)?

Ionis Pharmaceuticals (IONS) has a market capitalization of $6.91B. The average daily trading volume is 1.16M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level